---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-034793"
form_type: "8-K"
ticker: "FOXO"
cik: "0001812360"
company_name: "FOXO TECHNOLOGIES INC."
filed_at: "2026-07-27T20:05:22+00:00"
generated_at: "2026-07-27T20:08:19.997964+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# FOXO Tech unit Vector BioSource to buy 4 blood centers from Grifols for $3.5M plus earn-out

## Summary
- Vector BioSource, a FOXO subsidiary, agreed to buy four blood collection centers from Grifols Bio Supplies for $3.5M cash at closing.
- Earn-out of up to $1M payable if acquired business generates EBITDA of $1.5M or more in any calendar year 2026-2028.
- Closing conditioned on Vector obtaining new FDA license, CLIA certification, and waste-management permit independent of seller.
- Closing expected in Q3 or Q4 2026; long stop date is nine months from July 22, 2026.
- Acquired assets include serum inventory and existing cell units at the four collection centers.

## SEC filing metadata
- accession: 0001493152-26-034793
- form_type: 8-K
- ticker: FOXO
- cik: 0001812360
- company_name: FOXO TECHNOLOGIES INC.
- filed_at: 2026-07-27T20:05:22+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812360/000149315226034793/0001493152-26-034793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812360/000149315226034793/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-034793
- JSON: https://secwatch.observer/filing/0001493152-26-034793.json
- Plain text: https://secwatch.observer/filing/0001493152-26-034793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.